
 
 
 
 
 
 
 
 
 What is claimed is: 
   
 1. An anti-c-Met/anti-Ang2 bispecific antibody comprising: (a) an anti-c-Met antibody or an antigen-binding fragment thereof and (b) an anti-Ang2 antibody or an antigen-binding fragment thereof, wherein
 the anti-Ang2 antibody or an antigen-binding fragment thereof comprises: 
 (a) a CDR-H1 comprising SEQ ID NO: 109, a CDR-H2 comprising SEQ ID NO: 115, and a CDR-H3 comprising SEQ ID NO: 122;
 and 
 a CDR-L1 comprising SEQ ID NO: 130, a CDR-L2 comprising SEQ ID NO: 138; and a CDR-L3 comprising SEQ ID NO: 145; 
 
 (b) a CDR-H1 comprising SEQ ID NO: 110, a CDR-H2 comprising SEQ ID NO: 116, and a CDR-H3 comprising SEQ ID NO: 123;
 and 
 a CDR-L1 comprising SEQ ID NO: 131, a CDR-L2 comprising SEQ ID NO: 139; and a CDR-L3 comprising SEQ ID NO: 146; 
 
 (c) a CDR-H1 comprising SEQ ID NO: 111, a CDR-H2 comprising SEQ ID NO: 117, and a CDR-H3 comprising SEQ ID NO: 124;
 and 
 a CDR-L1 comprising SEQ ID NO: 132, a CDR-L2 comprising SEQ ID NO: 140; and a CDR-L3 comprising SEQ ID NO: 147; 
 
 (d) a CDR-H1 comprising SEQ ID NO: 109, a CDR-H2 comprising SEQ ID NO: 118, and a CDR-H3 comprising SEQ ID NO: 125;
 and 
 a CDR-L1 comprising SEQ ID NO: 133, a CDR-L2 comprising SEQ ID NO: 141; and a CDR-L3 comprising SEQ ID NO: 145; 
 
 (e) a CDR-H1 comprising SEQ ID NO: 112, a CDR-H2 comprising SEQ ID NO: 119, and a CDR-H3 comprising SEQ ID NO: 126;
 and 
 a CDR-L1 comprising SEQ ID NO: 134, a CDR-L2 comprising SEQ ID NO: 138; and a CDR-L3 comprising SEQ ID NO: 145; 
 
 (f) a CDR-H1 comprising SEQ ID NO: 109, a CDR-H2 comprising SEQ ID NO: 118, and a CDR-H3 comprising SEQ ID NO: 127;
 and 
 a CDR-L1 comprising SEQ ID NO: 135, a CDR-L2 comprising SEQ ID NO: 142; and a CDR-L3 comprising SEQ ID NO: 148; or 
 
 (g) a CDR-H1 comprising SEQ ID NO: 113, a CDR-H2 comprising SEQ ID NO: 120, and a CDR-H3 comprising SEQ ID NO: 128;
 and 
 a CDR-L1 comprising SEQ ID NO: 136, a CDR-L2 comprising SEQ ID NO: 143; and a CDR-L3 comprising SEQ ID NO: 149. 
 
 
 
     
 2. The anti-c-Met/anti-Ang2 bispecific antibody of  claim 1 , wherein the anti-Ang2 antibody or an antigen-binding fragment thereof comprises:
 (a) a heavy chain variable region comprising SEQ ID NO: 156; 
 and a light chain variable region comprising SEQ ID NO: 164; 
 (b) a heavy chain variable region comprising SEQ ID NO: 157; 
 and a light chain variable region comprising SEQ ID NO: 165; 
 (c) a heavy chain variable region comprising SEQ ID NO: 158; 
 and a light chain variable region comprising SEQ ID NO: 166; 
 (d) a heavy chain variable region comprising SEQ ID NO: 159; 
 and a light chain variable region comprising SEQ ID NO: 167; 
 (e) a heavy chain variable region comprising SEQ ID NO: 160; 
 and a light chain variable region comprising SEQ ID NO: 168; 
 (f) a heavy chain variable region comprising SEQ ID NO: 161; 
 and a light chain variable region comprising SEQ ID NO: 169; or 
 (g) a heavy chain variable region comprising SEQ ID NO: 162; 
 and a light chain variable region comprising SEQ ID NO: 170. 
 
 
     
 3. The anti-c-Met/anti-Ang2 bispecific antibody of  claim 1 , comprising an anti-c-Met antibody that comprises two heavy chains and two light chains, and an anti-Ang2 scFv linked to the C-terminus of the anti-c-Met antibody. 
 
     
 4. A pharmaceutical composition comprising the anti-c-Met/anti-Ang2 bispecific antibody of  claim 1  and a pharmaceutically acceptable carrier. 
 
     
 5. A method of treating a disease associated with c-Met or Ang2 in a subject, the method comprising administering the anti-c-Met/anti-Ang2 bispecific antibody of  claim 1  to the subject, wherein the a disease associated with c-Met or Ang2 is cancer or cancer metastasis. 
 
   
 
 
 
 
 
 
 
 
